TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO
La presente divulgación se refiere a métodos para mejorar la eficacia de terapias que implican células efectoras inmunitarias tales como células T diseñadas para expresar receptores de antígenos tales como receptores de células T (TCR) o receptores de antígenos quiméricos (CAR). En el presente docum...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | RENGSTL, BENJAMIN JAHNDEL, VERONIKA SAHIN, UGUR KUNA, KATHRIN KLEIN, OLIVER OUCHAN, YASMINA BIRTEL, MATTHIAS HAYDUK, NINA BILLMEIER, ARNE MICHEL, KRISTINA OEHM, PETRA REINHARD, KATHARINA |
| description | La presente divulgación se refiere a métodos para mejorar la eficacia de terapias que implican células efectoras inmunitarias tales como células T diseñadas para expresar receptores de antígenos tales como receptores de células T (TCR) o receptores de antígenos quiméricos (CAR). En el presente documento se demuestra que tales células efectoras inmunitarias diseñadas por receptor de antígeno, incluso cuando se proporcionan a un sujeto en cantidades subterapéuticas, son extremadamente eficaces en el tratamiento de enfermedades cancerosas, incluso aquellas enfermedades cancerosas que se sabe que son difíciles de tratar con células efectoras inmunitarias diseñadas por receptor de antígeno, tales como tumores sólidos o cánceres, si además se proporciona al sujeto antígeno diana para el receptor de antígeno. Las células efectoras inmunitarias se pueden diseñar ex vivo o in vitro y, posteriormente, las células efectoras inmunitarias se pueden administrar a un sujeto que necesite tratamiento, o las células efectoras inmunitarias se pueden diseñar in vivo en un sujeto que necesite tratamiento.
The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_AR120894A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>AR120894A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_AR120894A13</originalsourceid><addsrcrecordid>eNrjZEgMCXIMcfT1dPUL8VcIDHVV8PQL8_cJdQ5yVHA-3OkT6uMYrODq5uoc4h8EZHn6-Yb6eYY4BnkCOS6ewa6HJzq6AJkBjkD1Qa7OrgFAda5AKVcFR7-Qw73urn7-PAysaYk5xam8UJqbQd7NNcTZQze1ID8-tbggMTk1L7Uk3jHI0MjAwtLE0dCYsAoAMqg1dw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO</title><source>esp@cenet</source><creator>RENGSTL, BENJAMIN ; JAHNDEL, VERONIKA ; SAHIN, UGUR ; KUNA, KATHRIN ; KLEIN, OLIVER ; OUCHAN, YASMINA ; BIRTEL, MATTHIAS ; HAYDUK, NINA ; BILLMEIER, ARNE ; MICHEL, KRISTINA ; OEHM, PETRA ; REINHARD, KATHARINA</creator><creatorcontrib>RENGSTL, BENJAMIN ; JAHNDEL, VERONIKA ; SAHIN, UGUR ; KUNA, KATHRIN ; KLEIN, OLIVER ; OUCHAN, YASMINA ; BIRTEL, MATTHIAS ; HAYDUK, NINA ; BILLMEIER, ARNE ; MICHEL, KRISTINA ; OEHM, PETRA ; REINHARD, KATHARINA</creatorcontrib><description>La presente divulgación se refiere a métodos para mejorar la eficacia de terapias que implican células efectoras inmunitarias tales como células T diseñadas para expresar receptores de antígenos tales como receptores de células T (TCR) o receptores de antígenos quiméricos (CAR). En el presente documento se demuestra que tales células efectoras inmunitarias diseñadas por receptor de antígeno, incluso cuando se proporcionan a un sujeto en cantidades subterapéuticas, son extremadamente eficaces en el tratamiento de enfermedades cancerosas, incluso aquellas enfermedades cancerosas que se sabe que son difíciles de tratar con células efectoras inmunitarias diseñadas por receptor de antígeno, tales como tumores sólidos o cánceres, si además se proporciona al sujeto antígeno diana para el receptor de antígeno. Las células efectoras inmunitarias se pueden diseñar ex vivo o in vitro y, posteriormente, las células efectoras inmunitarias se pueden administrar a un sujeto que necesite tratamiento, o las células efectoras inmunitarias se pueden diseñar in vivo en un sujeto que necesite tratamiento.
The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment.</description><language>spa</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220330&DB=EPODOC&CC=AR&NR=120894A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220330&DB=EPODOC&CC=AR&NR=120894A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>RENGSTL, BENJAMIN</creatorcontrib><creatorcontrib>JAHNDEL, VERONIKA</creatorcontrib><creatorcontrib>SAHIN, UGUR</creatorcontrib><creatorcontrib>KUNA, KATHRIN</creatorcontrib><creatorcontrib>KLEIN, OLIVER</creatorcontrib><creatorcontrib>OUCHAN, YASMINA</creatorcontrib><creatorcontrib>BIRTEL, MATTHIAS</creatorcontrib><creatorcontrib>HAYDUK, NINA</creatorcontrib><creatorcontrib>BILLMEIER, ARNE</creatorcontrib><creatorcontrib>MICHEL, KRISTINA</creatorcontrib><creatorcontrib>OEHM, PETRA</creatorcontrib><creatorcontrib>REINHARD, KATHARINA</creatorcontrib><title>TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO</title><description>La presente divulgación se refiere a métodos para mejorar la eficacia de terapias que implican células efectoras inmunitarias tales como células T diseñadas para expresar receptores de antígenos tales como receptores de células T (TCR) o receptores de antígenos quiméricos (CAR). En el presente documento se demuestra que tales células efectoras inmunitarias diseñadas por receptor de antígeno, incluso cuando se proporcionan a un sujeto en cantidades subterapéuticas, son extremadamente eficaces en el tratamiento de enfermedades cancerosas, incluso aquellas enfermedades cancerosas que se sabe que son difíciles de tratar con células efectoras inmunitarias diseñadas por receptor de antígeno, tales como tumores sólidos o cánceres, si además se proporciona al sujeto antígeno diana para el receptor de antígeno. Las células efectoras inmunitarias se pueden diseñar ex vivo o in vitro y, posteriormente, las células efectoras inmunitarias se pueden administrar a un sujeto que necesite tratamiento, o las células efectoras inmunitarias se pueden diseñar in vivo en un sujeto que necesite tratamiento.
The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZEgMCXIMcfT1dPUL8VcIDHVV8PQL8_cJdQ5yVHA-3OkT6uMYrODq5uoc4h8EZHn6-Yb6eYY4BnkCOS6ewa6HJzq6AJkBjkD1Qa7OrgFAda5AKVcFR7-Qw73urn7-PAysaYk5xam8UJqbQd7NNcTZQze1ID8-tbggMTk1L7Uk3jHI0MjAwtLE0dCYsAoAMqg1dw</recordid><startdate>20220330</startdate><enddate>20220330</enddate><creator>RENGSTL, BENJAMIN</creator><creator>JAHNDEL, VERONIKA</creator><creator>SAHIN, UGUR</creator><creator>KUNA, KATHRIN</creator><creator>KLEIN, OLIVER</creator><creator>OUCHAN, YASMINA</creator><creator>BIRTEL, MATTHIAS</creator><creator>HAYDUK, NINA</creator><creator>BILLMEIER, ARNE</creator><creator>MICHEL, KRISTINA</creator><creator>OEHM, PETRA</creator><creator>REINHARD, KATHARINA</creator><scope>EVB</scope></search><sort><creationdate>20220330</creationdate><title>TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO</title><author>RENGSTL, BENJAMIN ; JAHNDEL, VERONIKA ; SAHIN, UGUR ; KUNA, KATHRIN ; KLEIN, OLIVER ; OUCHAN, YASMINA ; BIRTEL, MATTHIAS ; HAYDUK, NINA ; BILLMEIER, ARNE ; MICHEL, KRISTINA ; OEHM, PETRA ; REINHARD, KATHARINA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_AR120894A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>spa</language><creationdate>2022</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>RENGSTL, BENJAMIN</creatorcontrib><creatorcontrib>JAHNDEL, VERONIKA</creatorcontrib><creatorcontrib>SAHIN, UGUR</creatorcontrib><creatorcontrib>KUNA, KATHRIN</creatorcontrib><creatorcontrib>KLEIN, OLIVER</creatorcontrib><creatorcontrib>OUCHAN, YASMINA</creatorcontrib><creatorcontrib>BIRTEL, MATTHIAS</creatorcontrib><creatorcontrib>HAYDUK, NINA</creatorcontrib><creatorcontrib>BILLMEIER, ARNE</creatorcontrib><creatorcontrib>MICHEL, KRISTINA</creatorcontrib><creatorcontrib>OEHM, PETRA</creatorcontrib><creatorcontrib>REINHARD, KATHARINA</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>RENGSTL, BENJAMIN</au><au>JAHNDEL, VERONIKA</au><au>SAHIN, UGUR</au><au>KUNA, KATHRIN</au><au>KLEIN, OLIVER</au><au>OUCHAN, YASMINA</au><au>BIRTEL, MATTHIAS</au><au>HAYDUK, NINA</au><au>BILLMEIER, ARNE</au><au>MICHEL, KRISTINA</au><au>OEHM, PETRA</au><au>REINHARD, KATHARINA</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO</title><date>2022-03-30</date><risdate>2022</risdate><abstract>La presente divulgación se refiere a métodos para mejorar la eficacia de terapias que implican células efectoras inmunitarias tales como células T diseñadas para expresar receptores de antígenos tales como receptores de células T (TCR) o receptores de antígenos quiméricos (CAR). En el presente documento se demuestra que tales células efectoras inmunitarias diseñadas por receptor de antígeno, incluso cuando se proporcionan a un sujeto en cantidades subterapéuticas, son extremadamente eficaces en el tratamiento de enfermedades cancerosas, incluso aquellas enfermedades cancerosas que se sabe que son difíciles de tratar con células efectoras inmunitarias diseñadas por receptor de antígeno, tales como tumores sólidos o cánceres, si además se proporciona al sujeto antígeno diana para el receptor de antígeno. Las células efectoras inmunitarias se pueden diseñar ex vivo o in vitro y, posteriormente, las células efectoras inmunitarias se pueden administrar a un sujeto que necesite tratamiento, o las células efectoras inmunitarias se pueden diseñar in vivo en un sujeto que necesite tratamiento.
The present disclosure relates to methods for enhancing the efficiency of therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells, even when provided to a subject in sub-therapeutic amounts, are extremely effective in the treatment of cancer diseases, even those cancer diseases that are known to be difficult to treat with antigen receptor-engineered immune effector cells, such as solid tumors or cancers, if additionally target antigen for the antigen receptor is provided to the subject. Immune effector cells may be engineered ex vivo or in vitro and subsequently the immune effector cells may be administered to a subject in need of treatment, or immune effector cells may be engineered in vivo in a subject in need of treatment.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | spa |
| recordid | cdi_epo_espacenet_AR120894A1 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE |
| title | TRATAMIENTO QUE INVOLUCRA CÉLULAS EFECTORAS INMUNITARIAS DISEÑADAS PARA RECEPTORES DE ANTÍGENO |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T11%3A06%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=RENGSTL,%20BENJAMIN&rft.date=2022-03-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EAR120894A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |